Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Spruce Biosciences, Inc. (SPRB)
Company Research
Source: Business Wire
Topline Data from CAHmelia-204 Study of Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Anticipated in December 2024Topline Data from CAHptain-205 Study of Tildacerfont in Adult and Pediatric CAH Anticipated in December 2024Cash Runway Through the End of 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2024 and provided corporate updates.“We remain on track to report primary efficacy and safety data plus interim data from the open-label extension of the CAHmelia-204 study of tildacerfont in adult CAH patients in December 2024. At the same time, we will also report topline dose-ranging efficacy and safety data from the CAHptain-205 study of tildacerfont in adult and pediatric CAH pati
Show less
Read more
Impact Snapshot
Event Time:
SPRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRB alerts
High impacting Spruce Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
SPRB
News
- Spruce Biosciences, Inc. (NASDAQ: SPRB) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Spruce Biosciences, Inc. (NASDAQ: SPRB) had its "neutral" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Spruce Biosciences, Inc. (NASDAQ: SPRB) was downgraded by analysts at Citizens Jmp from a "strong-buy" rating to a "hold" rating.MarketBeat
- Spruce Biosciences, Inc. (NASDAQ: SPRB) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $1.50 price target on the stock, down previously from $2.00.MarketBeat
- Spruce Biosciences, Inc. (NASDAQ: SPRB) had its "market perform" rating re-affirmed by analysts at JMP Securities.MarketBeat
SPRB
Sec Filings
- 12/20/24 - Form 4
- 12/20/24 - Form 4
- 12/20/24 - Form 4
- SPRB's page on the SEC website